Judah Frommer
Stock Analyst at Morgan Stanley
(3.93)
# 553
Out of 5,172 analysts
186
Total ratings
62.41%
Success rate
5.2%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Maintains: Overweight | $19 → $18 | $10.61 | +69.65% | 3 | Mar 18, 2026 | |
| ZBIO Zenas BioPharma | Maintains: Equal-Weight | $19 → $21 | $22.30 | -5.83% | 3 | Mar 17, 2026 | |
| RGNX REGENXBIO | Maintains: Overweight | $18 → $17 | $8.10 | +109.88% | 4 | Mar 6, 2026 | |
| BLTE Belite Bio | Maintains: Overweight | $191 → $201 | $154.59 | +30.02% | 2 | Mar 3, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiates: Overweight | $28 | $12.19 | +129.70% | 1 | Mar 3, 2026 | |
| GMAB Genmab | Reinstates: Equal-Weight | $34 | $25.10 | +35.46% | 1 | Feb 16, 2026 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $101 → $145 | $120.34 | +20.49% | 4 | Jan 9, 2026 | |
| EVMN Evommune | Initiates: Overweight | $36 | $23.33 | +54.31% | 1 | Dec 1, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $17.21 | +51.07% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $30.90 | +39.16% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $31 → $22 | $32.01 | -31.27% | 3 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $6 | $8.61 | -30.31% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $81 → $106 | $114.77 | -7.64% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $18.41 | +90.11% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $1.93 | +55.44% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $1.23 | +3,152.03% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $2.67 | +386.89% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $33.51 | -31.36% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $65.30 | -23.43% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $16.69 | +744.82% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $3.49 | +157.88% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $28.94 | -23.98% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $4.97 | +40.85% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $6.77 | +18.17% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $60.92 | -24.49% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.55 | +174.51% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $16.09 | +241.83% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $136.00 | -66.18% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $81.03 | -39.53% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $972.33 | -61.95% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $89.40 | -65.32% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $81.33 | -6.55% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $124.52 | +46.16% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $105.92 | +1.02% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $98.96 | -4.00% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $17.29 | +4.11% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $227.42 | -48.99% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $97.04 | -60.84% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $81.80 | -73.11% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $73.20 | -52.19% | 9 | Apr 29, 2020 |
Trevi Therapeutics
Mar 18, 2026
Maintains: Overweight
Price Target: $19 → $18
Current: $10.61
Upside: +69.65%
Zenas BioPharma
Mar 17, 2026
Maintains: Equal-Weight
Price Target: $19 → $21
Current: $22.30
Upside: -5.83%
REGENXBIO
Mar 6, 2026
Maintains: Overweight
Price Target: $18 → $17
Current: $8.10
Upside: +109.88%
Belite Bio
Mar 3, 2026
Maintains: Overweight
Price Target: $191 → $201
Current: $154.59
Upside: +30.02%
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Overweight
Price Target: $28
Current: $12.19
Upside: +129.70%
Genmab
Feb 16, 2026
Reinstates: Equal-Weight
Price Target: $34
Current: $25.10
Upside: +35.46%
ABIVAX Société Anonyme
Jan 9, 2026
Maintains: Overweight
Price Target: $101 → $145
Current: $120.34
Upside: +20.49%
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: $36
Current: $23.33
Upside: +54.31%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $17.21
Upside: +51.07%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $30.90
Upside: +39.16%
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $32.01
Upside: -31.27%
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $8.61
Upside: -30.31%
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $114.77
Upside: -7.64%
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $18.41
Upside: +90.11%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $1.93
Upside: +55.44%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $1.23
Upside: +3,152.03%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $2.67
Upside: +386.89%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $33.51
Upside: -31.36%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $65.30
Upside: -23.43%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $16.69
Upside: +744.82%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $3.49
Upside: +157.88%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $28.94
Upside: -23.98%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $4.97
Upside: +40.85%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $6.77
Upside: +18.17%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $60.92
Upside: -24.49%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.55
Upside: +174.51%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $16.09
Upside: +241.83%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $136.00
Upside: -66.18%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $81.03
Upside: -39.53%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $972.33
Upside: -61.95%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $89.40
Upside: -65.32%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $81.33
Upside: -6.55%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $124.52
Upside: +46.16%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $105.92
Upside: +1.02%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $98.96
Upside: -4.00%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $17.29
Upside: +4.11%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $227.42
Upside: -48.99%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $97.04
Upside: -60.84%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $81.80
Upside: -73.11%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $73.20
Upside: -52.19%